Patents by Inventor Gregor W. Leckie

Gregor W. Leckie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for identifying drug resistant tuberculosis
    Patent number: 11225693
    Abstract: Provided herein are compositions and methods for diagnosing and characterizing tuberculosis infection. In particular, provided herein are compositions and methods for identifying drug resistant tuberculosis.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: January 18, 2022
    Assignee: ABBOTT MOLECULAR INC.
    Inventors: Hong Wang, Gregor W. Leckie, Vihanga Pahalawatta, Klara Abravaya, Joshua Kostera, Ning Tang, Andrea Frank
  • COMPOSITIONS AND METHODS FOR IDENTIFYING DRUG RESISTANT TUBERCULOSIS
    Publication number: 20200080135
    Abstract: Provided herein are compositions and methods for diagnosing and characterizing tuberculosis infection. In particular, provided herein are compositions and methods for identifying drug resistant tuberculosis.
    Type: Application
    Filed: November 22, 2019
    Publication date: March 12, 2020
    Inventors: Hong Wang, Gregor W. Leckie, Vihanga Pahalawatta, Klara Abravaya, Joshua Kostera, Ning Tang, Andrea Frank
  • Compositions and methods for identifying drug resistant tuberculosis
    Patent number: 10526664
    Abstract: Provided herein are compositions and methods for diagnosing and characterizing tuberculosis infection. In particular, provided herein are compositions and methods for identifying drug resistant tuberculosis.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: January 7, 2020
    Assignee: Abbott Molecular Inc.
    Inventors: Hong Wang, Gregor W. Leckie, Vihanga Pahalawatta, Klara Abravaya, Joshua Kostera, Ning Tang, Andrea Frank
  • Hepatitis B virus typing and resistance assay
    Patent number: 10526667
    Abstract: The present invention provides methods, kits, and oligonucleotides for detecting and analyzing the nucleotide sequence of a reverse transcriptase (RT) region of the polymerase (Pol) gene of Hepatitis B Virus (HBV). In certain embodiments, a target RT region is amplified and subjected to DNA sequencing. The sequence obtained is compared to one or more DNA sequences characteristic of an HBV genotype or serotype, and/or one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine, to determine the HBV genotype or serotype of the amplified product and/or the presence or absence of one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 7, 2020
    Assignee: ABBOTT MOLECULAR INC.
    Inventors: Gregor W. Leckie, Reuben J. Ofsaiof, Roy M. Vijesurier, Hong Wang
  • COMPOSITIONS AND METHODS FOR IDENTIFYING DRUG RESISTANT TUBERCULOSIS
    Publication number: 20170044594
    Abstract: Provided herein are compositions and methods for diagnosing and characterizing tuberculosis infection. In particular, provided herein are compositions and methods for identifying drug resistant tuberculosis.
    Type: Application
    Filed: July 13, 2016
    Publication date: February 16, 2017
    Inventors: Hong Wang, Gregor W. Leckie, Vihanga Pahalawatta, Klara Abravaya, Joshua Kostera, Ning Tang, Andrea Frank
  • HEPATITIS B VIRUS TYPING AND RESISTANCE ASSAY
    Publication number: 20150259755
    Abstract: The present invention provides methods, kits, and oligonucleotides for detecting and analyzing the nucleotide sequence of a reverse transcriptase (RT) region of the polymerase (Pol) gene of Hepatitis B Virus (HBV). In certain embodiments, a target RT region is amplified and subjected to DNA sequencing. The sequence obtained is compared to one or more DNA sequences characteristic of an HBV genotype or serotype, and/or one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine, to determine the HBV genotype or serotype of the amplified product and/or the presence or absence of one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine.
    Type: Application
    Filed: April 30, 2015
    Publication date: September 17, 2015
    Inventors: Gregor W. Leckie, Reuben J. Ofsaiof, Roy M. Vijesurier, Hong Wang
  • Hepatitis B virus typing and resistance assay
    Patent number: 9045803
    Abstract: The present invention provides methods, kits, and oligonucleotides for detecting and analyzing the nucleotide sequence of a reverse transcriptase (RT) region of the polymerase (Pol) gene of Hepatitis B Virus (HBV). In certain embodiments, a target RT region is amplified and subjected to DNA sequencing. The sequence obtained is compared to one or more DNA sequences characteristic of an HBV genotype or serotype, and/or one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine, to determine the HBV genotype or serotype of the amplified product and/or the presence or absence of one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 2, 2015
    Assignee: Abbott Molecular Inc.
    Inventors: Gregor W. Leckie, Reuben J. Ofsaiof, Roy M. Vijesurier, Hong Wang
  • HEPATITIS B VIRUS TYPING AND RESISTANCE ASSAY
    Publication number: 20130252232
    Abstract: The present invention provides methods, kits, and oligonucleotides for detecting and analyzing the nucleotide sequence of a reverse transcriptase (RT) region of the polymerase (Pol) gene of Hepatitis B Virus (HBV). In certain embodiments, a target RT region is amplified and subjected to DNA sequencing. The sequence obtained is compared to one or more DNA sequences characteristic of an HBV genotype or serotype, and/or one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine, to determine the HBV genotype or serotype of the amplified product and/or the presence or absence of one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine.
    Type: Application
    Filed: February 22, 2013
    Publication date: September 26, 2013
    Applicant: ABBOTT MOLECULAR INC.
    Inventors: Gregor W. Leckie, Reuben J. Ofsaiof, Roy M. Vijesurier, Hong Wang
  • MOLECULAR DETECTION OF XMRV INFECTION
    Publication number: 20120058462
    Abstract: The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. In particular, the invention relates to XMRV-related nucleic acids having significant diagnostic and screening utilities and methods of using the same.
    Type: Application
    Filed: August 18, 2011
    Publication date: March 8, 2012
    Applicant: Abbott Laboratories
    Inventors: Ning Tang, Gregor W. Leckie
  • MOLECULAR DETECTION OF XMRV INFECTION
    Publication number: 20120058461
    Abstract: The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. In particular, the invention relates to XMRV-related nucleic acids having significant diagnostic and screening utilities and methods of using the same.
    Type: Application
    Filed: August 18, 2011
    Publication date: March 8, 2012
    Applicant: Abbott Laboratories
    Inventors: Ning Tang, Gregor W. Leckie
  • Method for removing amplification inhibitors from test samples
    Publication number: 20040170991
    Abstract: Provided herein is a method for removing nucleic acid amplification reaction inhibitors from test samples.
    Type: Application
    Filed: June 17, 2003
    Publication date: September 2, 2004
    Applicant: Abbott Laboratories
    Inventors: Folim G. Halaka, Dwight Erickson, Qizhi He, Gregor W. Leckie, Bor-Chian Lin
  • Materials and methods for the detection of mycobacterium tuberculosis
    Patent number: 5786149
    Abstract: The present invention is directed to oligonucleotides useful in detection, e.g., by ligase chain reaction (LCR) of target DNA from Mycobacterium tuberculosis. The present invention is also directed to methods of detecting target DNAs from Mycobacterium tuberculosis.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: July 28, 1998
    Assignee: Abbott Laboratories
    Inventors: Gregor W. Leckie, Alan H. Davis, Ingrid E. Semple-Facey, Matthew T. Manlove, Natalie A. Solomon
  • Materials and methods for the detection of Mycobacterium tuberculosis
    Patent number: 5631130
    Abstract: The present invention is directed to oligonucleotides useful in detection, e.g., by ligase chain reaction (LCR) of target DNA from Mycobacterium tuberculosis. The present invention is also directed to methods of detecting target DNAs from Mycobacterium tuberculosis.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: May 20, 1997
    Assignee: Abbott Laboratories
    Inventors: Gregor W. Leckie, Alan H. Davis, Ingrid E. Semple-Facey, Matthew T. Manlove, Natalie A. Solomon